$FBLGJun 22, 2026, 12:30 PMAI processed
USPTO allows FibroBiologics patent for topical fibroblast‑spheroid wound therapy
AI Summary
The USPTO issued a Notice of Allowance for U.S. Patent Application No. 18/184,726 covering topical administration of 3D spheroid fibroblasts, alone or with fibroblast-derived materials, to treat and accelerate healing of wounds including chronic wounds and wounds in diabetic patients. The allowed claims map directly to FibroBiologics' lead program CYWC628 (an allogeneic topical fibroblast‑spheroid therapy currently in a Phase 1/2 diabetic foot ulcer trial), strengthening IP around the clinical approach though no clinical efficacy data were reported.
Positives
- USPTO issued Notice of Allowance for U.S. Patent Application No. 18/184,726 covering topical 3D spheroid fibroblasts ± fibroblast-derived materials
- Allowed claims explicitly cover treatment of chronic wounds and patients with diabetes
- Claims align with and protect the company’s lead CYWC628 program (Phase 1/2 diabetic foot ulcer trial)
Negatives
- Notice of Allowance is not the issued patent; final grant and enforceability remain subject to issuance and potential challenges
- Announcement contains no clinical efficacy or trial readout data
- CYWC628 remains in early-stage (Phase 1/2) development and clinical/commercial outcomes are uncertain